These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35324094)

  • 1. Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Comorbid Depressive and Anxiety Disorders.
    Ravindran N; McKay M; Paric A; Johnson S; Chandrasena R; Abraham G; Ravindran AV
    J Clin Psychiatry; 2022 Mar; 83(3):. PubMed ID: 35324094
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study.
    McIntyre A; Paisley D; Kouassi E; Gendron A
    Arthritis Rheumatol; 2014 Feb; 66(2):451-61. PubMed ID: 24504819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
    Cutler AJ; Montgomery SA; Feifel D; Lazarus A; Aström M; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):526-39. PubMed ID: 19358790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial.
    Gao K; Wu R; Kemp DE; Chen J; Karberg E; Conroy C; Chan P; Ren M; Serrano MB; Ganocy SJ; Calabrese JR
    J Clin Psychiatry; 2014 Oct; 75(10):1062-8. PubMed ID: 25007003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder.
    Locklear JC; Svedsäter H; Datto C; Endicott J
    J Affect Disord; 2013 Jul; 149(1-3):189-95. PubMed ID: 23639212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
    J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study.
    Chen YC; Chen CK; Wang LJ
    BMC Psychiatry; 2012 Sep; 12():162. PubMed ID: 23020711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial.
    Li H; Gu N; Zhang H; Wang G; Tan Q; Yang F; Ning Y; Zhang H; Lu Z; Xu X; Shi J; Gao C; Li L; Zhang K; Tian H; Wang X; Li K; Li H; Xu Y; Xie S; Yu X
    Psychopharmacology (Berl); 2016 Apr; 233(7):1289-97. PubMed ID: 26911380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
    Wang Z; Kemp DE; Chan PK; Fang Y; Ganocy SJ; Calabrese JR; Gao K
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):131-42. PubMed ID: 20875219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine: a review of its use in the management of bipolar depression.
    Sanford M; Keating GM
    CNS Drugs; 2012 May; 26(5):435-60. PubMed ID: 22519923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.
    Findling RL; Pathak S; Earley WR; Liu S; DelBello MP
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):325-35. PubMed ID: 24956042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.
    Maneeton N; Maneeton B; Srisurapanont M; Martin SD
    BMC Psychiatry; 2012 Sep; 12():160. PubMed ID: 23017200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
    J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.
    Weisler R; Joyce M; McGill L; Lazarus A; Szamosi J; Eriksson H;
    CNS Spectr; 2009 Jun; 14(6):299-313. PubMed ID: 19668121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.